Skroot Laboratory is a technology company.
Skroot Laboratory has raised $25K across 1 funding round.
Skroot Laboratory has raised $25K in total across 1 funding round.
Skroot Laboratory is a biotechnology company specializing in wireless process analytical technologies (PAT) designed for cell and protein therapy development, particularly in upstream bioprocess design. Their core product is the SMART Platform, a sensor system that enables continuous, contact-free monitoring of cell cultures inside closed incubators and bioreactors. This technology eliminates the need for manual sampling, reducing contamination risk and streamlining the manufacturing of personalized cell therapies. Skroot serves biopharmaceutical developers and researchers focused on personalized medicine, addressing the costly and labor-intensive challenges in cell therapy production. The company is gaining momentum through strategic partnerships and federal funding, positioning itself to impact a market projected to exceed $100 billion by 2030[1][2][4].
Founded in 2018 by Dr. Nigel Reuel, a chemical and biological engineering expert at Iowa State University, Skroot Laboratory emerged from the need to simplify and improve the manufacturing process of personalized cell therapies. The company’s name, derived from a Polish word meaning "shortcut," reflects its mission to streamline complex bioprocesses. Early validation came through NSF Phase I and II SBIR awards and CARES Act funding, supporting the development of their innovative sensor technology. A pivotal moment was joining the NSF Engineering Research Center for Cell Manufacturing Technologies (CMaT), which connected Skroot with academic and industry collaborators to advance cell therapy discovery[1][2].
Skroot Laboratory rides the wave of personalized medicine and cell therapy, a rapidly growing sector driven by advances in biotechnology and increasing demand for tailored treatments. The timing is critical as current personalized cell therapies are prohibitively expensive (around half a million dollars per dose), limiting patient access. Skroot’s technology addresses key manufacturing bottlenecks by enabling real-time, non-invasive monitoring, which can reduce costs and improve scalability. This aligns with broader market forces favoring automation, data-driven bioprocessing, and decentralized manufacturing. By integrating into consortia like CMaT, Skroot influences the ecosystem by fostering collaboration between academia, industry, and clinical partners to accelerate innovation in cell therapy manufacturing[2][1].
Looking ahead, Skroot Laboratory is poised to expand its impact by refining its sensor technology and scaling adoption within the personalized medicine sector. Trends such as increasing demand for cell and gene therapies, advances in bioprocess automation, and regulatory emphasis on process analytical technologies will shape its trajectory. As costs decrease and manufacturing becomes more efficient, Skroot’s solutions could democratize access to life-saving therapies, extending their influence beyond biotech labs to mainstream clinical applications. Their ongoing partnerships and federal support suggest a strong foundation for growth and innovation in the coming years[2][1].
Skroot Laboratory has raised $25K in total across 1 funding round.
Skroot Laboratory's investors include Ag Startup Engine.
Skroot Laboratory has raised $25K across 1 funding round. Most recently, it raised $25K Seed in February 2020.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Feb 1, 2020 | $25K Seed | Ag Startup Engine |